News & Events

ObsEva in the News
View All News

ObsEva SA to Attend Needham Annual Healthcare Conference in NYC

24 Mar 2017


Geneva, Switzerland – 24 March 2017 – ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today announced that Ernest LOUMAYE, M.D., Ph.D., CEO and Co-Founder and Tim ADAMS, CFO, will attend the 16th Annual Needham Healthcare Conference. Management will be presenting on Tuesday April 4 at 3:40 pm and will be hosting one-on-one meetings on April 4 and 5, 2017 at the Westin New York Grand Central Hotel.

About ObsEva

ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving ART outcomes. ObsEva is listed on The NASDAQ Global Select Market and is trading under the ticker symbol "OBSV". For more information, please visit www.ObsEva.com.

###

Media Contact:

Liz Bryan

Spectrum Science

lbryan@spectrumscience.com

202-955-6222 x2526

Company Contact:

Delphine Renaud

ObsEva, CEO Office

delphine.renaud@obseva.ch

+41 22 552 1550

 

Media Contact

Liz Bryan
Spectrum
+1 (202) 955 6222
lbryan@spectrumscience.com